Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Advanced Solid Tumors.

Part of paid clinical trials in Harvey, Illinois.

Sponsor
Herbert Hurwitz
Study ID
NCT00849550
Phase
PHASE1
Status
Completed

Conditions

  • Cancer
  • Unspecified Adult Solid Tumor, Protocol Specific

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to determine if RAD001 (everolimus) helps improve the standard treatment of XELOX-A (bevacizumab, oxaliplatin, capecitabine) in advanced solid tumors.

Key Dates

First listed
Feb 24, 2009
Start date
Jul 31, 2009
Status verified
Dec 2012
Primary completion
Dec 31, 2012
Completion
Dec 31, 2012

Study Design

Enrollment
32 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: XELOX-A-Ev

Primary Outcome Measure

To determine the MTD/RPTD of capecitabine/oxaliplatin/bevacizumab/everolimus (XELOX-A-Ev) for subjects with advanced solid tumors. [ Time Frame: End of treatment phase ]

Locations (3)

FacilityCityStateZIPSite coordinators
Ingalls Cancer Research CenterHarveyIllinois60426-
Duke University Medical CenterDurhamNorth Carolina27710-
Sarah Cannon Research InstituteNashvilleTennessee37203-

Find similar trials in Harvey, IL

By research site
Ingalls Cancer Research Center· Harvey, ILDuke University Medical Center· Durham, NCSarah Cannon Research Institute· Nashville, TN

Related Studies